Tumor microenvironment and redox dual stimuli-responsive polymeric nanoparticles for the effective cisplatin-based cancer chemotherapy

Jia, Yiyang; Huan, Meng‐Lei; Wang, Wei; Jia, Zhou-Yan; Wan, Yu-Hang; Zhou, Siyuan; Zhang, Bang-Le

doi:10.1088/1361-6528/ac990e

Cited by 3 publications

(1 citation statement)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Stimuli-responsive materials have been employed in drug delivery systems to enable the controlled and targeted release of metallodrugs in response to specific physiological or pathological stimuli, such as pH, temperature, enzymes, or redox conditions. For example, pH-responsive polymeric nanoparticles have been developed for the targeted delivery of cisplatin, demonstrating enhanced tumor penetration and controlled drug release in response to the acidic tumor microenvironment ( Jia et al, 2022 ). This approach can further improve the therapeutic index of metallodrugs by ensuring selective release at the tumor site and minimizing off-target effects.…”

Section: Resultsmentioning

confidence: 99%

Metallodrugs in the battle against non-small cell lung cancer: unlocking the potential for improved therapeutic outcomes

Xu,

Dai,

Mao

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Non-small cell lung cancer (NSCLC) remains a leading cause of cancer mortality worldwide. Platinum-based chemotherapy is standard-of-care but has limitations including toxicity and resistance. Metal complexes of gold, ruthenium, and other metals have emerged as promising alternatives. This review provides a comprehensive analysis of metallodrugs for NSCLC. Bibliometric analysis reveals growing interest in elucidating mechanisms, developing targeted therapies, and synergistic combinations. Classification of metallodrugs highlights platinum, gold, and ruthenium compounds, as well as emerging metals. Diverse mechanisms include DNA damage, redox modulation, and immunomodulation. Preclinical studies demonstrate cytotoxicity and antitumor effects in vitro and in vivo, providing proof-of-concept. Clinical trials indicate platinums have utility but resistance remains problematic. Non-platinum metallodrugs exhibit favorable safety but modest single agent efficacy to date. Drug delivery approaches like nanoparticles show potential to enhance therapeutic index. Future directions include optimization of metal-based complexes, elucidation of resistance mechanisms, biomarker development, and combination therapies to fully realize the promise of metallodrugs for NSCLC.

show abstract

Section: Resultsmentioning

confidence: 99%

Metallodrugs in the battle against non-small cell lung cancer: unlocking the potential for improved therapeutic outcomes

Xu,

Dai,

Mao

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

Preparation and Evaluation of Paclitaxel-Loaded Reactive Oxygen Species and Glutathione Redox-Responsive Poly(Lactic-Co-Glycolic Acid) Nanoparticles for Controlled Release in Tumor Cells

Wang

Han

Xie

et al. 2022

Nanomedicine (Lond.)

View full text Add to dashboard Cite

Anticancer Activity of Metallodrugs and Metallizing Host Defense Peptides—Current Developments in Structure-Activity Relationship

Andrés,

Pérez de la Lastra,

Bustamante Munguira

et al. 2024

IJMS

View full text Add to dashboard Cite

This article provides an overview of the development, structure and activity of various metal complexes with anti-cancer activity. Chemical researchers continue to work on the development and synthesis of new molecules that could act as anti-tumor drugs to achieve more favorable therapies. It is therefore important to have information about the various chemotherapeutic substances and their mode of action. This review focuses on metallodrugs that contain a metal as a key structural fragment, with cisplatin paving the way for their chemotherapeutic application. The text also looks at ruthenium complexes, including the therapeutic applications of phosphorescent ruthenium(II) complexes, emphasizing their dual role in therapy and diagnostics. In addition, the antitumor activities of titanium and gold derivatives, their side effects, and ongoing research to improve their efficacy and reduce adverse effects are discussed. Metallization of host defense peptides (HDPs) with various metal ions is also highlighted as a strategy that significantly enhances their anticancer activity by broadening their mechanisms of action.

show abstract

Tumor microenvironment and redox dual stimuli-responsive polymeric nanoparticles for the effective cisplatin-based cancer chemotherapy

Cited by 3 publications

References 52 publications

Metallodrugs in the battle against non-small cell lung cancer: unlocking the potential for improved therapeutic outcomes

Metallodrugs in the battle against non-small cell lung cancer: unlocking the potential for improved therapeutic outcomes

Preparation and Evaluation of Paclitaxel-Loaded Reactive Oxygen Species and Glutathione Redox-Responsive Poly(Lactic-Co-Glycolic Acid) Nanoparticles for Controlled Release in Tumor Cells

Anticancer Activity of Metallodrugs and Metallizing Host Defense Peptides—Current Developments in Structure-Activity Relationship

Contact Info

Product

Resources

About